We serve Chemical Name:17-Hydroxy sprengerinin C CAS:1029017-75-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:17-Hydroxy sprengerinin C
CAS.NO:1029017-75-1
Synonyms:17-HYDROXY SPRENGERININ C;Hydroxy Sprengerinin C, 17-
Molecular Formula:C44H70O17
Molecular Weight:871.01600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:255.91000
Exact Mass:870.46100
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 17-HYDROXY SPRENGERININ C chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Hydroxy Sprengerinin C, 17- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,17-HYDROXY SPRENGERININ C Use and application,17-HYDROXY SPRENGERININ C technical grade,usp/ep/jp grade.
Related News: The company’s product reserves are rich, with more than one hundred varieties in various categories from intermediates to APIs. At present, the grays and anti-hepatitis C series intermediates are steadily advancing, which will ensure future growth. 17-Hydroxy sprengerinin C manufacturer But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. 17-Hydroxy sprengerinin C supplier Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anaemia). Patients with higher-risk MDS may progress to the development of acute leukaemia. 17-Hydroxy sprengerinin C vendor He said the FDA made its decision by fiat, and had not asked its advisors to consider whether the drug’s ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. 17-Hydroxy sprengerinin C factory The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population.